This site is intended for adult US residents only.

Foursight Prostate Cancer imaging logo
  • Home
  • Unmet need in PCa imaging
  • Technology - PET
  • Target - PSMA
  • Tracer - 18F
  • Tools - AI systems
Sign up for updates

Sitemap


  • Home
    • Unmet need in PCa imaging
  • Technology, Target, Tracer, Tools
    • Technology - PET
    • Target - PSMA
    • Tracer - 18F
    • Tools - AI systems
  • Registration
Technology-PET icon

Technology

See why today’s PCa imaging is suboptimal and reimagine it with PET1

Learn more >
Technology-PET icon

Technology

See why today’s PCa imaging is suboptimal and reimagine it with PET1

Learn more >
Target-PSMA icon

Target

Discover how specific targeting of PSMA may result in improved diagnostic accuracy2,3

Learn more >
Target-PSMA icon

Target

Discover how specific targeting of PSMA may result in improved diagnostic accuracy2,3

Learn more >
Tracer-18F icon

Tracer

Explore how the high spatial resolution and low positronic emission of 18F may result in high‑quality images6

Learn more >
Tracer-18F icon

Tracer

Explore how the high spatial resolution and low positronic emission of 18F may result in high‑quality images6

Learn more >
Tools-AI systems icon

Tools

Consider the potential of increasing the consistency and accuracy of image reporting with AI systems5,7

Learn more >
Tools-AI systems icon

Tools

Consider the potential of increasing the consistency and accuracy of image reporting with AI systems5,7

Learn more >

References:
1. Alipour R, Azad A, Hofman MS. Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? Ther Adv Med Oncol. 2019;11:1-14. doi:10.1177/1758835919876828.
2. Petersen L, Zacho HD. PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer; an expedited systematic review. Cancer Imaging. 2020;1-8. doi:10.1186/s40644-020-0290-9
3. Tan N, Oyoyo U, Bavadian N, et al. PSMA-targeted radiotracers versus 18F fluciclovine for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis. Radiology. 2020;296:44-55. /doi.org/10.1148/radiol.2020191689
4. Werner RA, Derlin T, Lapa C, et al. 18F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging. Theranostics. 2020;10(1):1‐16.
5. Duffy IR, Boyle AJ, Vasdev N. Improving PET imaging acquisition and analysis with machine learning: a narrative review with focus on alzheimer’s disease and oncology. Molecular Imaging. 2019;18:1-11. doi:10.1177/1536012119869070
6. Data on file. Progenics Pharmaceuticals, Inc.

Lantheus Holdings logo
  • Contact Us
  • Privacy Policy
  • Legal Notice
  • Compliance
  • Sitemap

Intended for U.S. residents only.
Trademarks, registered or otherwise, are the property of their respective owner(s).
Use of this information is subject to the terms of our Legal Notice and Privacy Policy.
©2022 Progenics Pharmaceuticals, Inc., a Lantheus company. All rights reserved.
331 Treble Cove Road, N. Billerica, MA 01862
Phone: 1-800-362-26681-800-362-2668

PM-US-PY-0316 August 2022